Here are 1-3 brief analogies for Immunic (IMUX):

• An early-stage **Biogen** focused on developing oral therapies for autoimmune and inflammatory diseases like multiple sclerosis.
• A clinical-stage **Vertex Pharmaceuticals**, but developing oral, targeted treatments for autoimmune and inflammatory diseases.

• IMU-838: A selective oral immunology therapy in Phase 2 clinical trials for treating multiple sclerosis, inflammatory bowel disease, other chronic inflammatory and autoimmune diseases, and coronavirus disease.
• IMU-935: An inverse agonist of ROR?t, currently under development.
• IMU-856: A therapy being developed for the restoration of the intestinal barrier function in patients suffering from conditions like inflammatory bowel disease and irritable bowel syndrome with diarrhea.

Immunic, Inc. (IMUX) is a clinical-stage biopharmaceutical company focused on developing therapies for chronic inflammatory and autoimmune diseases. As a company in the clinical development stage, it does not currently have commercial products on the market. Therefore, Immunic, Inc. does not have major customers in the traditional sense of companies or individuals purchasing its products or services.

Dr. Daniel Vitt, Chief Executive Officer and Director

Dr. Vitt joined Immunic in January 2017 and has served as Chief Executive Officer, President, and Director since its reverse takeover transaction in 2019. He co-founded the biotech company 4SC AG in 1997, where he served as Chief Scientific Officer and Chief Development Officer, helping to grow it from a research-stage startup into an advanced therapeutic development organization with multiple clinical-stage candidates. Dr. Vitt is also a member of the advisory board of the venture capital fund "Wachstumsfond Bayern 2" and co-founded Brauhaus Germering GmbH in 2018.

Glenn Whaley, Chief Financial Officer

Mr. Whaley joined Immunic in December 2019 as Principal Accounting Officer and Controller, was promoted to Vice President Finance in April 2020, and became Chief Financial Officer in March 2022. He brings over 30 years of experience in accounting and finance. Prior to Immunic, he held increasing responsibilities at Pernix Therapeutics, serving most recently as Vice President of Finance. He also served as Vice President of Finance for Alvogen, Inc. and Corporate Controller for ImClone Systems.

Jason Tardio, President and Chief Operating Officer

Mr. Tardio was appointed President and Chief Operating Officer, effective July 12, 2024. He is a seasoned biopharmaceutical executive with extensive experience in the commercialization of multiple sclerosis (MS) drugs, having held pivotal roles at Novartis and Biogen, where he was instrumental in launching and managing products that generated significant revenue.

Dr. Hella Kohlhof, Chief Scientific Officer

Dr. Kohlhof joined Immunic in January 2017 as Chief Scientific Officer, where she is responsible for the company's scientific strategy. She also serves as Managing Director of Immunic's research subsidiary, Immunic Research GmbH. Previously, she worked at 4SC AG, starting as a scientific group leader in 2008 and later serving as Director of Development Projects, where she was responsible for the entire product development pipeline, including IMU-838 and IMU-935.

Dr. Andreas Muehler, Chief Medical Officer

Dr. Muehler was part of the initial founding team of Immunic AG in 2016. He plays a significant role in the company's clinical development, frequently discussing Immunic's pipeline and clinical trial results, particularly concerning treatments for Inflammatory Bowel Disease and Multiple Sclerosis.

The key risks for Immunic (IMUX), a clinical-stage biopharmaceutical company, are primarily centered around the inherent challenges of drug development, financial sustainability, and market dynamics.

1. Clinical Development and Regulatory Approval Risk

   As a clinical-stage company, Immunic's business success is fundamentally dependent on the successful outcome of its ongoing and future clinical trials and subsequent regulatory approvals for its product candidates, particularly IMU-838. Clinical trials are inherently risky, and there is no guarantee that current or future trials will yield favorable results, even if earlier-stage data were promising. Failure can occur at any stage of development, leading to significant delays or the complete cessation of a program. For example, IMU-838 previously failed a Phase 2 trial for ulcerative colitis, and IMU-935 showed disappointing interim Phase 1b results in psoriasis due to high placebo rates. Immunic's lead asset, vidofludimus calcium (IMU-838), is currently in pivotal Phase 3 ENSURE trials for relapsing multiple sclerosis, with top-line data anticipated by the end of 2026. The outcome of these trials represents a "binary outcome risk" for the company, where negative results could severely impact the stock and future prospects. Furthermore, even with positive trial results, obtaining regulatory marketing approval from agencies like the FDA is a complex and lengthy process, with constantly shifting requirements that can lead to delays or outright rejection.

2. Financial Sustainability and Funding Risk

   Immunic is a pre-commercial, clinical-stage company that does not generate revenue from product sales and has consistently incurred operating losses since its inception. The company's significant research and development (R&D) expenditures, which were substantial at $63.0 million for the first nine months of 2025, contribute to a high cash burn rate. Immunic has explicitly stated that its cash and cash equivalents, which were approximately $35.1 million as of September 30, 2025, are insufficient to fund operations for a full 12 months without raising additional capital. This ongoing need for financing introduces substantial "going concern" risk and the potential for further dilution of existing shareholders through equity offerings. The ability to secure sufficient funding on acceptable terms is critical for the continued development of its pipeline and overall business continuity.

3. Competition and Market Acceptance Risk

   The therapeutic areas Immunic targets, such as chronic inflammatory and autoimmune diseases, are highly competitive. Even if a product candidate successfully navigates clinical development and gains regulatory approval, its commercial success will depend on its ability to compete effectively with existing treatments and other pipeline drugs from larger, more established pharmaceutical companies. Factors such as pricing pressures, market access, reimbursement policies, and public acceptance of new therapies will significantly influence a product's commercial viability. Delays in Immunic's clinical trials could also allow competitors to bring similar products to market sooner, reducing Immunic's potential market share and commercial opportunities.

Immunic, Inc. (IMUX) is anticipated to drive future revenue growth over the next 2-3 years through the advancement and potential commercialization of its lead drug candidates, primarily focusing on its multiple sclerosis (MS) program and the emerging potential of its gastrointestinal and metabolic pipeline.

Here are 3-5 expected drivers of future revenue growth for Immunic:

1. Regulatory Approval and Commercial Launch of IMU-838 (vidofludimus calcium) for Relapsing Multiple Sclerosis (RMS): Immunic's lead asset, IMU-838, is currently in Phase 3 ENSURE-1 and ENSURE-2 clinical trials for RMS, with top-line data expected by the end of 2026. Successful completion of these trials and subsequent regulatory approvals would pave the way for the commercial launch of IMU-838, positioning it as a novel oral therapy in the global MS market, which is projected to exceed $30 billion by the early 2030s. The company has already initiated preparations to transition into a commercial-stage organization, including seeking a new CEO with commercial expertise in MS.

2. Expansion of IMU-838 into Progressive Multiple Sclerosis (PMS) and Primary Progressive Multiple Sclerosis (PPMS): Beyond RMS, IMU-838 has shown positive Phase 2 data in Progressive Multiple Sclerosis (PMS), highlighting its neuroprotective potential. Immunic plans to initiate a Phase 3 trial in Primary Progressive Multiple Sclerosis (PPMS). Expanding IMU-838's indications to include these forms of MS would significantly broaden its addressable market and contribute to long-term revenue growth.

3. Advancement of IMU-856 in Celiac Disease: Immunic is currently preparing for Phase 2 testing of IMU-856 in patients with ongoing active celiac disease (OACD). Early results from a Phase 1b trial showed promising improvements in bowel histology, disease symptoms, biomarkers, and nutrient absorption in celiac disease patients. Successful progression through later-stage clinical trials and eventual market approval for IMU-856 would address a significant unmet medical need and create a new revenue stream for Immunic.

4. Development of IMU-856 for Weight Management: New data reported in February 2025 indicated that IMU-856 demonstrated a dose-dependent increase in GLP-1 levels in celiac disease patients and corresponding effects in preclinical testing, suggesting its potential as an oral treatment for obesity. With the global obesity market expected to exceed $170 billion by 2031, successful development and potential commercialization of IMU-856 in weight management could represent a substantial future revenue driver.

• In February 2026, Immunic announced a private placement that is expected to generate gross proceeds of up to $400 million, including $200 million upfront, to fund its clinical trials and transition into a commercial organization.
• In May 2025, the company priced an underwritten public offering with initial gross proceeds expected to be approximately $65 million, with a potential for up to an additional $130 million if associated warrants are fully exercised.
• In May 2024, Immunic filed a prospectus for an at-the-market (ATM) sales agreement allowing for the offering, issuance, and sale of up to $80.0 million of common stock, which rolled over unsold common stock from a May 2022 ATM.

• In February 2026, Immunic secured up to $400 million through an oversubscribed private placement led by existing investor BVF Partners L.P., with participation from several institutional investors including Aberdeen Investments, Avidity Partners, OrbiMed, and RA Capital Management.
• The May 2025 public offering was co-led by BVF Partners and Coastlands Capital, and included participation from Aberdeen Investments, Adage Capital Partners LP, and Janus Henderson Investors.
• In January 2024, Immunic entered into a three-tranche private placement agreement that could potentially raise up to $240 million, with the first tranche closing with gross proceeds of $80 million.

• Immunic's investing cash flow, primarily capital expenditures, was negligible at approximately -$0.14 million for the twelve months leading up to mid-2025, which is typical for a company focused on intellectual property and clinical trials.
• The proceeds from the February 2026 private placement are expected to fund operating and capital expenditures into late 2027.
• The primary focus of capital allocation, reflected in significant research and development expenses (e.g., $82.0 million in 2025 and $80.0 million in 2024), is the ongoing clinical development of its lead product candidates, particularly the Phase 3 ENSURE trials for IMU-838 in relapsing multiple sclerosis and the initiation of a Phase 3 program in primary progressive multiple sclerosis.